Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1MR9

Crystal structure of Streptogramin A Acetyltransferase with acetyl-CoA bound

1MR9 の概要
エントリーDOI10.2210/pdb1mr9/pdb
関連するPDBエントリー1MR7 1MRL
分子名称Streptogramin A Acetyltransferase, ACETYL COENZYME *A (2 entities in total)
機能のキーワードleft-handed parallel-beta helix domain, transferase
由来する生物種Enterococcus faecium
タンパク質・核酸の鎖数6
化学式量合計149160.34
構造登録者
Kehoe, L.E.,Snidwongse, J.,Courvalin, P.,Rafferty, J.B.,Murray, I.A. (登録日: 2002-09-18, 公開日: 2003-08-26, 最終更新日: 2024-11-13)
主引用文献Kehoe, L.E.,Snidwongse, J.,Courvalin, P.,Rafferty, J.B.,Murray, I.A.
Structural Basis of Synercid (Quinupristin-Dalfopristin) Resistance in Gram-positive Bacterial Pathogens
J.Biol.Chem., 278:29963-29970, 2003
Cited by
PubMed Abstract: Synercid, a new semisynthetic streptogramin-derived antibiotic containing dalfopristin and quinupristin, is used in treatment of life-threatening infections caused by glycopeptide-resistant Enterococcus faecium and other bacterial pathogens. However, dissemination of genes encoding virginiamycin acetyltransferases, enzymes that confer resistance to streptogramins, threatens to limit the medical utility of the quinupristin-dalfopristin combination. Here we present structures of virginiamycin acetyltransferase D (VatD) determined at 1.8 A resolution in the absence of ligands, at 2.8 A resolution bound to dalfopristin, and at 3.0 A resolution in the presence of acetyl-coenzyme A. Dalfopristin is bound by VatD in a similar conformation to that described previously for the streptogramin virginiamycin M1. However, specific interactions with the substrate are altered as a consequence of a conformational change in the pyrollidine ring that is propagated to adjacent constituents of the dalfopristin macrocycle. Inactivation of dalfopristin involves acetyl transfer from acetyl-coenzyme A to the sole (O-18) hydroxy group of the antibiotic that lies close to the side chain of the strictly conserved residue, His-82. Replacement of residue 82 by alanine is accompanied by a fall in specific activity of >105-fold, indicating that the imidazole moiety of His-82 is a major determinant of catalytic rate enhancement by VatD. The structure of the VatD-dalfopristin complex can be used to predict positions where further structural modification of the drug might preclude enzyme binding and thereby circumvent Synercid resistance.
PubMed: 12771141
DOI: 10.1074/jbc.M303766200
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3 Å)
構造検証レポート
Validation report summary of 1mr9
検証レポート(詳細版)ダウンロードをダウンロード

252091

件を2026-04-15に公開中

PDB statisticsPDBj update infoContact PDBjnumon